The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study.
 
Daniel Reinhorn
Honoraria - AstraZeneca; Bristol-Myers Squibb Israel; MSD
 
Sandra D'Angelo
Honoraria - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Medendi; Nektar; Pfizer; Rain Therapeutics; Ratio therapeutics; Replimune; Servier
Research Funding - Amgen; Bristol-Myers Squibb.; Deciphera; EMD Serono; Incyte; Merck; Nektar
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
Other Relationship - Adaptimmune; GlaxoSmithKline; Merck; Nektar
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Avacta Life Sciences; Bayer; Boehringer Ingelheim; C4 Therapeutics; Curadev; Daiichi Sankyo; Deciphera; Ikena Oncology; IMGT; inhibrx; Ipsen; PharmaEssential; Ratio; Servier; Sonata
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Ciara Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - Deciphera; Kartos Therapeutics; SERVIER
Research Funding - Amgen (Inst); Curadev (Inst); IDRx (Inst); InhibRx (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst); Servier (Inst); xencor (Inst)
Travel, Accommodations, Expenses - Deciphera
 
Mrinal Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Epizyme; Ikena Oncology; Kura Oncology; Rain Therapeutics
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Vivace Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Mary Louise Keohan
No Relationships to Disclose
 
Michael Ortiz
No Relationships to Disclose
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Ascentage Pharma Group (Inst); Hutchison MediPharma (Inst); Jaz (Inst); Pfizer (Inst); Pfizer (Inst); PTC (Inst); Trillium Therapeutics (Inst)
 
Evan Rosenbaum
Stock and Other Ownership Interests - Iovance Biotherapeutics; PMV Pharma
Research Funding - Arcus Biosciences; GlaxoSmithKline; Incyte
 
Aimee Crago
Honoraria - Wolters Kluwer
Consulting or Advisory Role - Springworks Therapeutics
Patents, Royalties, Other Intellectual Property - Patent assigned to MSKCC for a companion diagnostic to CDK4 inhibitors - Patent number 9,889,135 (Inst)
Travel, Accommodations, Expenses - Deciphera
 
Samuel Singer
No Relationships to Disclose
 
Minsi Zhang
No Relationships to Disclose
 
Kaled Alektiar
No Relationships to Disclose
 
Mark Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)